Abstract
Since the feasibility of stem cell therapy has been recognized, enthusiasm for this therapy has grown exponentially. Nevertheless, as professionals we must realize that this enthusiasm should relate not only to our scientific interest but also to the care of our patients. Within the next decade, patients' demand for the latest therapies is likely to rise because of changes in health care systems that will broaden availability. Stem cell therapy is likely to be among these in-demand treatments, and we must be prepared for this change. In this Review we discuss the basic principles of how to launch a clinical program for stem cell therapy for cardiovascular repair. First, we look at the composition of the program team. Second, we describe the different types of stem cells available in clinical practice. Third, we present in depth the two most widely applicable delivery approaches. Finally, we discuss selection of patients and approaches and clinical and imaging methods by which to evaluate the safety and efficacy of this therapy.
Key Points
-
Preparations must be made for a rise in patients' demand for the latest therapies, including those still under investigation
-
A stem cell therapy program requires a multidisciplinary team, including cardiologists, hematologists, cardiovascular surgeons, imaging experts, basic scientists, and other professionals
-
A program's success should be assessed by surrogate endpoints, predicting changes in prognosis and quality of life, until the mechanisms of stem cell therapy are more clearly defined
-
With the information currently available, guessing the impact of stem cell therapy on survival is difficult and patients with various prognoses need to be studied
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Strauer BE et al. (2002) Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation 106: 1913–1918
Fernandez-Aviles F et al. (2004) Experimental and clinical regenerative capability of human bone marrow cells after myocardial infarction. Circ Res 95: 742–748
Bartunek J et al. (2006) The consensus of the task force of the European Society of Cardiology concerning the clinical investigation of the use of autologous adult stem cells for repair of the heart. Eur Heart J 27: 1338–1340
Orlic D et al. (2001) Bone marrow cells regenerate infarcted myocardium. Nature 410: 701–705
Saha M and Ferro A (2006) Cardiac stem cell therapy: present and future. Br J Clin Pharmacol 61: 727–729
Grigoropoulus NF and Mathur A (2006) Stem cells in cardiac repair. Curr Opin Pharmacol 6: 169–175
Sánchez PL et al. (2006) Contemplating the bright future of stem cell therapy for cardiovascular disease. Nat Clin Pract Cardiovasc Med 3 (Suppl 1): S138–S151
Herreros J et al. (2003) Autologous intramyocardial injection of cultured skeletal muscle-derived stem cells in patients with non-acute myocardial infarction. Eur Heart J 24: 2012–2020
Menasche P et al. (2003) Autologous skeletal myoblast transplantation for severe postinfarction left ventricular dysfunction. J Am Coll Cardiol 41: 1078–1083
Assmus B et al. (2006) Transcoronary transplantation of progenitor cells after myocardial infarction. N Engl J Med 355: 1222–1232
Schachinger V et al. (2006) Intracoronary bone marrow derived progenitor cells in acute myocardial infarction. N Engl J Med 355: 1210–1221
Lunde K et al. (2006) Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. N Engl J Med 355: 1199–1209
Schatteman GC and Awad O (2004) Hemangioblasts, angioblasts, and adult endothelial cell progenitors. Anat Rec A Discov Mol Cell Evol Biol 276: 13–21
Dohmann HF et al. (2005) Transendocardial autologous bone marrow mononuclear cell injection in ischemic heart failure: postmortem anatomicopathologic and immunohistochemical findings. Circulation 112: 521–526
Ozbaran M et al. (2004) Autologous peripheral stem cell transplantation in patients with congestive heart failure due to ischemic heart disease. Eur J Cardiothorac Surg 25: 342–350
Kang HJ et al. (2004) Effects of intracoronary infusion of peripheral blood stem cells mobilised with granulocyte-colony stimulating factor on left ventricular systolic function and restenosis after coronary stenting in myocardial infarction: The MAGIC cell randomised clinical trial. Lancet 363: 751–756
Stamm C et al. (2003) Autologous bone-marrow stem-cell transplantation for myocardial regeneration. Lancet 361: 45–46
Zipori D (2004) Mesenchymal stem cells: harnessing cell plasticity to tissue and organ repair. Blood Cells Mol Dis 33: 211–215
Xu W et al. (2004) Mesenchymal stem cells from adult human bone marrow differentiate into a cardiomyocyte phenotype in vitro. Exp Biol Med 229: 623–631
Valiunas V et al. (2004) Human mesenchymal stem cells make cardiac connexins and form functional gap junction. J Physiol 555: 617–626
Silva GV et al. (2005) Mesenchymal stem cells differentiate into an endothelial phenotype, enhance vascular density, and improve heart function in a canine chronic ischemic model. Circulation 111: 150–156
Pittenger MF and Martin BJ (2004) Mesenchymal stem cells and their potential as cardiac therapeutics. Circulation Res 95: 9–20
Menasche P et al. (2006) Routine delivery of myoblasts during coronary artery bypass surgery: why not? Nat Clin Pract Cardiovasc Med 3 (Suppl 1): S90–S93
Villa A et al. (2006) Intracoronary human bone marrow stem cell transplantation in acute myocardial infarction and ventricular arrhythmias [abstract]. J Am Coll Cardiol 47: 44
Fuster V et al. (2006) The utility of magnetic resonance imaging in cardiac tissue regeneration trials. Nat Clin Pract Cardiovasc Med 3 (Suppl 1): S2–S7
San Roman JA and Fernandez-Aviles F (2006) The role of noninvasive imaging techniques in the assessment of stem cell therapy after acute myocardial infarction. Nat Clin Pract Cardiovasc Med 3 (Suppl 1): S38–S41
Rosenzweig A (2006) Cardiac cell therapy—mixed results from mixed cells. N Engl J Med 355: 1274–1277
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Sánchez, P., Sánchez-Guijo, F., Villa, A. et al. Launching a clinical program of stem cell therapy for cardiovascular repair. Nat Rev Cardiol 4 (Suppl 1), S123–S129 (2007). https://doi.org/10.1038/ncpcardio0767
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncpcardio0767